ReviewEndocrine2020
Acromegaly in the elderly patients.
Review in Endocrine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Psychiatric morbidity in acromegaly: a cohort study and meta-analysis of the literature.Pituitary · 2025Pooled it
- Ageing and pituitary neuroendocrine tumours (PitNETs): from bench to bedside.Endocrine-related cancer · 2026Review
- Aging and rare diseases: from epidemiology to a call to action.European geriatric medicine · 2026Article
- The Journey of Acromegaly Towards Treatment: A Single-Center Study.Journal of personalized medicine · 2026Article
- Successful 15-year management of a 97-year-old woman with acromegaly: a case report and review of the literature.Journal of medical case reports · 2026Review
- Acromegaly in an elderly male with hepatic malignancy: a case report of a diagnostic dilemma.Annals of medicine and surgery (2012) · 2026Article
- Article
- Treatment-resistant Cushing disease and acromegaly in a young woman: A case of functional pituitary macroadenoma.Radiology case reports · 2025Article
- Diagnostic delay, older age, and hormonal levels at diagnosis affect disease burden and mortality in acromegaly.Journal of endocrinological investigation · 2025Article
- Hypopituitarism presenting with cardiovascular manifestations: a case report.BMC cardiovascular disorders · 2025Article
- Anatomical considerations in acromegalic patients: A multicentric cohort study.Surgical neurology international · 2025Article
- Acromegaly and COVID-19, lessons, and new opportunities.Pituitary · 2024Article
- The changing landscape of acromegaly - an epidemiological perspective.Reviews in endocrine & metabolic disorders · 2024Review
- Age-Related Hormones Changes and Its Impact on Health Status and Lifespan.Aging and disease · 2023Review
- Systemic comorbidities of acromegaly in real-life experience: which difference among young and elderly patients?Endocrine · 2023Article
- Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.Journal of endocrinological investigation · 2023Article
- Discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study.Frontiers in endocrinology · 2023Observational
- Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience.Pituitary · 2022Article
- Approach of Acromegaly during Pregnancy.Diagnostics (Basel, Switzerland) · 2022Review
- Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain.Frontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundAcromegaly is a rare disease characterized by a chronic exposition to growth hormone (GH) and insulin-like growth factor-1 (IGF-1), caused in most cases by a pituitary GH-secreting adenoma. Chronic GH excess induces systemic complications (metabolic, cardiovascular, respiratory, neoplastic, and musculoskeletal) and increased mortality if not appropriately treated. Recent epidemiological data report an improved life span of patients with acromegaly probably due to better acromegaly management; additionally, the number of pituitary incidentaloma in general population also increased over time due to more frequent imaging. Therefore, the number of elderly patients, newly diagnosed with acromegaly or in follow-up, is expected to grow in the coming years and clinicians will need to be aware of particularities in managing these patients. PURPOSE: This review aims to explore different aspects of acromegaly of the elderly patients, focusing on epidemiology, diagnosis, clinical presentation, complications, and management options.
methodsAvailable literature has been assessed through PubMed (data until August 2019) by specific keywords.
conclusionsAvailable data on acromegaly in the elderly patient are sparse, but point to important differences. Further studies are needed comparing elderly with younger patients with acromegaly to better define a tailored diagnostic and therapeutic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.